
Collective Mining Expands the Outcropping Portion of Apollo by Drilling High-Grade Tungsten, Copper, Gold and Silver Including 124 Metres at 3.03 g/t AuEq (0.66% WO3Eq) from Surface
High-grade tungsten, copper, silver and gold assay results have been received for the initial eight holes of a thirty-hole, shallow drilling program designed to outline, expand and design a future starter pit at the Apollo system. The Apollo system has been drilled over more than 1,200 metres vertically where it remains open for further expansion. The Apollo system can be separated vertically into four areas of metal zonation, with the top 150 metres from surface being a high-grade zone enriched in tungsten (scheelite), copper, gold and silver (see Figure 5).
Four holes have cut near surface, tungsten dominant, high-grade mineralization with highlighted results as follows:
124 metres @ 3.03 g/t AuEq or 0.66% WO 3 Eq (0.55 g/t gold, 86 g/t silver, 0.63% copper, and 0.16% WO 3) from surface (APC-115).
91 metres @ 3.04 g/t AuEq or 0.66% WO 3 Eq (0.85 g/t gold, 48 g/t silver, 0.39% copper and 0.32% WO 3) from 56.15 metres depth and bottoming in high-grade mineralization (APC-110).
The discovery of tungsten at Apollo is the first known hard-rock occurrence of this metal in the history of Colombia and is expected to be of strategic importance for the country. Given that the tungsten, hosted within easily recoverable scheelite, is located at the top of the Apollo system, it is expected to be extracted in the earliest portions of the mine-life as a by-product mineral to gold, silver and copper. Tungsten is a critical metal exempt from United States tariffs. Eighty per cent of the tungsten market is supplied by China and there is a looming 2027 deadline eliminating purchases by the United States military complex of tungsten produced or processed by China and Russia. Recently, the tungsten price has reached a twelve year high at approximately $14.75 per pound and is expected to remain buoyant over the foreseeable future (source: Reuters and Mining.com).
TORONTO, June 2, 2025 /CNW/ - Collective Mining Ltd. (NYSE: CNL) (TSX: CNL) ("Collective" or the "Company") is pleased to announce initial assay results for its shallow drilling program at the Apollo system ("Apollo"). Assay results for the first eight drill holes designed to test for high-grade gold, silver, copper and tungsten mineralization starting from surface are summarized in this release. Apollo is the most advanced discovery made to date within the Company's multi-target, Guayabales Project in Caldas, Colombia.
The Company currently has nine drill rigs operating as part of its fully funded 70,000-metre drill program for 2025 with seven rigs operating at the Guayabales Project and two rigs turning at the San Antonio Project. Two additional deep capacity rigs are being mobilized to the Guayabales Project to continue testing, at depth, the high-grade Ramp Zone located at the bottom of the Apollo system in early Q3, 2025.
The 2025 objectives for the portion of the drilling program targeting the Apollo system are:
Drill test newly modeled high-grade sub-zone targets scattered throughout the top 1,000 vertical metres from surface to improve the grade profile (and size) of the system.
Grow the overall dimensions of the system by expanding vertically and laterally the recently discovered high-grade Ramp Zone and the northern extensions of Apollo.
Expand and define the area of outcropping/shallow mineralization and test many drilling gaps within the internal block model from surface to a depth of 150 metres.
Approximately 123,000 metres of diamond drilling has been completed to date at the Guayabales Project, including 85,000 metres at Apollo. There are currently twenty-three drill holes in the lab with pending assay results for most of these holes expected in the near term.
Ari Sussman, Executive Chairman commented: "The occurrence of continuous high-grade tungsten alongside copper, gold and silver mineralization, beginning from surface and in the top portion of the Apollo system is a real bonus as this material will be extracted in the earlier years of a future mine and will contribute in placing Colombia on the map as an important critical mineral supplier in the Americas.
The next few months at the Guayabales project are going to be exciting with new larger capacity rigs scheduled to arrive and begin aggressively expanding the high-grade Ramp Zone at depth in Apollo. Additionally, we recently completed our first new hole at the early-stage ME target and will soon start drilling two new grassroot targets named the Knife and X. Drilling with two rigs has also begun at the San Antonio project, where we look to vector towards a potential high-grade copper-gold porphyry core to the recently announced discovery."
Details (see Table 1-2 and Figures 1-6)
A shallow, 30-hole drilling program recently commenced at Apollo and is now over 50% complete. Results have been received from the first eight holes from three new drill pads (Pads 21, 22 and 23) and have intersected shallow, high-grade gold, tungsten, copper and silver mineralization down to a maximum drilled depth of 150 metres below surface. Importantly, continuous intervals of high-grade tungsten (scheelite) and copper (chalcopyrite) mineralization have been intercepted in both the breccia cement matrix and within individual veins for holes drilled into the shallow and outcropping, tungsten rich area of Apollo. Assay results targeting the tungsten rich area of the system are outlined below:
91.00 metres @ 3.04 g/t AuEq or 0.66% WO 3 Eq (0.85 g/t gold, 48 g/t silver, 0.39% copper and 0.32% WO 3) from 56.15 metres down hole and bottoming in high-grade mineralization (APC-110 drilled steeply in a southerly direction from Pad 21).
117.35 metres @ 2.07 g/t AuEq or 0.45% WO 3 Eq (1.18 g/t gold, 26 g/t silver, 0.22% copper and 0.09% WO 3) from 14.25 metres down hole (APC-111 drilled to the southeast from Pad 21) including:
28.15 metres @ 4.89 g/t AuEq or 1.06% WO 3 Eq from 80.70 metres down hole.
99.00 metres @ 1.43 g/t AuEq or 0.31% WO 3 Eq from 6.00 metres down hole (APC-113 drilled to the southeast from Pad 22) including:
18.40 metres @ 2.66 g/t gold equivalent from 6.00 metres.
124.00 metres @ 3.03 g/t AuEq or 0.66% WO 3 Eq (0.55 g/t gold, 86 g/t silver, 0.63% copper and 0.16% WO 3) from surface (APC-115 drilled to the southwest from Pad 22).
An additional four holes targeted areas outside of the tungsten rich portion of the upper Apollo system with one of the holes expanding the previously known boundaries of the system to the east, two holes intersecting high-grade mineralization in gaps within the block model and a final exploratory hole failing to encounter any meaningful mineralization. Highlight results of these holes are as follows:
APC-108 was drilled to the ESE from Pad 21 and successfully expanded the shallow boundary of the system in this direction:
48.00 metres @ 0.86 g/t AuEq from 65.75 metres including:
16.95 metres @ 1.49 g/t AuEq 96.80 metres.
APC-114 was drilled to the west from Pad 23 and cut high-grade gold and copper mineralization just below surface with the following assays:
133.10 metres @ 2.68 g/t AuEq (1.54 g/t gold, 27 g/t silver, 0.54% copper and 0.03% WO 3) from 25.90 metres including:
60.35 metres @ 3.55 g/t AuEq from 71.80 metres.
Numerous additional shallow drill holes are currently being assayed with additional results expected in the near term.
Table 1: Assays Results for Drill Holes APC-110, APC-111, APC-113 and APC-115 Drilled into the Shallow and High-Grade Tungsten Rich Zone
*WO 3 Eq% is calculated as follows: (WO 3 (%) x 0.72) + (Au (g/t) x 0.22 x 0.97) + (Ag (g/t) x 0.003 x 0.85) + (Cu (%) x 0.31 x 0.95) utilizing metal prices of WO 3 – US$14.75/lb, Au – US$2,200/oz, Ag – US$33/oz and Cu – US$4.62/lb and recovery rates of 72% for WO 3, 97% for Au, 85% for Ag and 95% for Cu.
**AuEq (g/t) is calculated as follows: (Au (g/t) x 0.97) + (Ag (g/t) x 0.015 x 0.85) + (Cu (%) x 1.44 x 0.95) + (WO 3 (%) x 4.60 x 0.72) utilizing metal prices of Au – US$2,200/oz, Ag – US$33/oz, Cu – US$4.62/lb and WO 3 – US$14.75/lb and recovery rates of 97% for Au, 85% for Ag, 95% for Cu and 72% for WO 3.
Recovery rate assumptions for metals are based on metallurgical results announced on October 17, 2023, April 11, 2024, and October 3, 2024. True widths are unknown and grades are uncut.
Table 2: Assays Results for Drill Holes APC-108, APC-109, APC-112 and APC-114 Drilled into the Shallow High-Grade Mineralization
**AuEq (g/t) is calculated as follows: (Au (g/t) x 0.97) + (Ag (g/t) x 0.015 x 0.85) + (Cu (%) x 1.44 x 0.95) + (WO 3 (%) x 4.60 x 0.72) utilizing metal prices of Au – US$2,200/oz, Ag – US$33/oz, Cu – US$4.62/lb and WO 3 – US$14.75/lb and recovery rates of 97% for Au, 85% for Ag, 95% for Cu and 72% for WO 3. Recovery rate assumptions for metals are based on metallurgical results announced on October 17, 2023, April 11, 2024, and October 3, 2024. True widths are unknown and grades are uncut.
About Collective Mining Ltd.
To see our latest corporate presentation and related information, please visit www.collectivemining.com.
Founded by the team that developed and sold Continental Gold Inc. to Zijin Mining for approximately $2 billion in enterprise value, Collective is a gold, silver, copper and tungsten exploration company with projects in Caldas, Colombia. The Company has options to acquire 100% interests in two projects located directly within an established mining camp with ten fully permitted and operating mines.
The Company's flagship project, Guayabales, is anchored by the Apollo system, which hosts the large-scale, bulk-tonnage and high-grade gold-silver-copper-tungsten Apollo system. The Company's objectives are to improve the overall grade of the Apollo system by systematically drill testing newly modeled potentially high-grade sub-zones, expand the Apollo system by stepping out along strike to the north and expanding the newly discovered high-grade Ramp Zone along strike and to depth, and drill a series of less advanced or newly generated targets including Trap, the Knife and X.
Management, insiders, a strategic investor and close family and friends own 44.5% of the outstanding shares of the Company and as a result, are fully aligned with shareholders. The Company is listed on both the NYSE American and TSX under the trading symbol "CNL".
Qualified Person (QP) and NI43-101 Disclosure
David J Reading is the designated Qualified Person for this news release within the meaning of National Instrument 43-101 ("NI 43-101") and has reviewed and verified that the technical information contained herein is accurate and approves of the written disclosure of same. Mr. Reading has an MSc in Economic Geology and is a Fellow of the Institute of Materials, Minerals and Mining and of the Society of Economic Geology (SEG).
Technical Information
Samples were cut by Company personnel at Collective Mining's core facility in Caldas, Colombia. Diamond drill core was sawed and then sampled in maximum 2 metres intervals, stopping at geological boundaries. Drill hole core diameter is a mix of PQ, HQ and NQ depending on the depth of the drill hole.
Core samples have been prepared and analyzed at ALS laboratory facilities in Medellin, Colombia and Lima, Peru. Blanks, duplicates, and certified reference standards are inserted into the sample stream to monitor laboratory performance. Crush rejects and pulps are kept and stored in a secured storage facility for future assay verification. No capping has been applied to sample composites. The Company utilizes a rigorous, industry-standard QA/QC program.
Information Contact:
Follow Executive Chairman Ari Sussman (@Ariski73) on X
Follow Collective Mining (@CollectiveMini1) on X, (Collective Mining) on LinkedIn, and (@collectivemining) on Instagram
FORWARD-LOOKING STATEMENTS
This news release contains "forward-looking statements" and "forward-looking information" within the meaning of applicable securities legislation (collectively, "forward-looking statements"). All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussion with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often, but not always using phrases such as "plans", "expects", "is expected", "budget", "scheduled", "estimates", "forecasts", "intends", "anticipates", or "believes" or variations (including negative variations) of such words and phrases, or state that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved) are not statements of historical fact and may be forward-looking statements. In this news release, forward-looking statements relate, among other things, to: the anticipated advancement of mineral properties or programs; future operations; future recovery metal recovery rates; future growth potential of Collective; and future development plans.
These forward-looking statements, and any assumptions upon which they are based, are made in good faith and reflect our current judgment regarding future events including the direction of our business. Management believes that these assumptions are reasonable. Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include, among others: risks related to the speculative nature of the Company's business; the Company's formative stage of development; the Company's financial position; possible variations in mineralization, grade or recovery rates; actual results of current exploration activities; conclusions of future economic evaluations; fluctuations in general macroeconomic conditions; fluctuations in securities markets; fluctuations in spot and forward prices of gold, precious and base metals or certain other commodities; fluctuations in currency markets; change in national and local government, legislation, taxation, controls regulations and political or economic developments; risks and hazards associated with the business of mineral exploration, development and mining (including environmental hazards, industrial accidents, unusual or unexpected formation pressures, cave-ins and flooding); inability to obtain adequate insurance to cover risks and hazards; the presence of laws and regulations that may impose restrictions on mining; employee relations; relationships with and claims by local communities and indigenous populations; availability of increasing costs associated with mining inputs and labour; the speculative nature of mineral exploration and development (including the risks of obtaining necessary licenses, permits and approvals from government authorities); and title to properties, as well as those risk factors discussed or referred to in the annual information form of the Company dated March 24, 2025. Forward-looking statements contained herein are made as of the date of this news release and the Company disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or results, except as may be required by applicable securities laws. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements and there may be other factors that cause results not to be anticipated, estimated or intended. Accordingly, readers should not place undue reliance on forward-looking statements.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Cision Canada
17 minutes ago
- Cision Canada
KITS Announces Voting Results from 2025 Annual General Meeting of Shareholders
VANCOUVER, BC, June 4, 2025 /CNW/ - Kits Eyecare Ltd. (TSX: KITS) ("KITS" or the "Company") is pleased to announce the results of the matters voted upon at its annual general meeting of shareholders held on June 4, 2025 (the "Meeting"), which included the election of directors. All of the resolutions were conducted by electronic ballot and the voting results are set out below. 1. Election of Directors The following six nominees were elected by the shareholders as directors of the Company for the ensuing year and each of the directors received the following votes: 2. Re-appointment of MNP LLP as the Company's Auditors MNP LLP was re-appointed as the Company's auditors to hold office until the next annual meeting of shareholders of the Company (and the directors were authorized to fix their remuneration) as follows: About KITS KITS makes eyecare easy. KITS is a leading vertically integrated digital eyecare brand providing eyewear for eyes everywhere. We offer customers access to a vast selection of contact lenses and eyeglasses, including our own exclusive KITS designed products, as well as a robust suite of online vision tools. Our efficient digital platform, backed by our industry-leading manufacturing and designs, removes intermediaries, and enables us to offer great prices and deliver made to order personalized products with incredible care and accuracy. We are creating disruption in the industry by constantly pursuing cutting-edge technologies to enable the best customer experience, including online eyewear fitting tools, and virtual try-on for glasses. We strive to delight our customers with our competitive prices, a convenient digital shopping experience, fast and reliable delivery options, and an unrelenting focus on earning our customers' lifelong trust. For more information on KITS, visit:


Globe and Mail
2 hours ago
- Globe and Mail
You Need to Know This Before Buying or Selling BigBear.ai Stock
(NYSE: BBAI) is one of the most innovative AI companies globally. Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Learn More » *Stock prices used were the afternoon prices of May 31, 2025. The video was published on June 2, 2025. Should you invest $1,000 in right now? Before you buy stock in consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $651,049!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $828,224!* Now, it's worth noting Stock Advisor 's total average return is979% — a market-crushing outperformance compared to171%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of June 2, 2025 Parkev Tatevosian, CFA has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. Parkev Tatevosian is an affiliate of The Motley Fool and may be compensated for promoting its services. If you choose to subscribe through his link, he will earn some extra money that supports his channel. His opinions remain his own and are unaffected by The Motley Fool.


Cision Canada
2 hours ago
- Cision Canada
AI in Healthcare Just Crossed a Tipping Point. Investors Are Watching These Names
Issued on behalf of Avant Technologies Inc. VANCOUVER, BC, June 4, 2025 /CNW/ -- Equity Insider News Commentary – Generative AI is transforming healthcare faster than almost any other sector, according to a new McKinsey report. In a March survey of senior leaders across payers, providers, and healthcare services groups, 85% said they're actively using or exploring the technology. McKinsey's Global Institute estimates Gen AI could unlock $60–110 billion in annual value across pharma and medical products alone. With more AI pilot programs running than ever before, the tech world is racing to meet demand — including new efforts from Avant Technologies, Inc. (OTCQB: AVAI), Medtronic plc (NYSE: MDT), Butterfly Network, Inc. (NYSE: BFLY), Oracle Corporation (NYSE: ORCL), and Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX). Investor capital is pouring into AI-driven healthcare, with Pittsburgh-based Abridge AI Inc. pulling in $300 million at a $5.3 billion valuation. While several private players are making headlines, public markets are also heating up. Statista now projects the global AI healthcare market will soar from $11 billion to $188 billion by 2030 — a staggering 37% compound annual growth rate. Avant Technologies, Inc. (OTCQB: AVAI), in partnership with Ainnova Tech, is entering the final prototyping stage of a proprietary, automated retinal imaging device — marking a potential turning point in the companies' shared push toward AI-powered early diagnostics. The new device is designed to operate hands-free and feed imaging data directly into the Vision AI platform, enabling near-instant risk reports without expensive equipment or trained personnel. The companies say the camera, developed under their joint venture Ai-nova Acquisition Corp. (AAC), is expected to cost a fraction of legacy fundus cameras. By combining affordability with automation, the device could expand screening access across primary care clinics and emerging-market providers that have traditionally been priced out of ophthalmic diagnostics. "The cost of a fundus camera has always been a barrier to entry in this market," said Vinicio Vargas, CEO at Ainnova and board member of AAC. "Our low-cost camera, which is a fraction of the cost of currently available cameras on the market, should allow us to not only enter the market, but to capture a large share of the market." But hardware is only half the story. The new camera is being built to integrate seamlessly with Vision AI, Ainnova's diagnostic platform that uses retinal imaging, vital signs, and basic lab inputs to assess risk for a range of diseases. Already in use across clinical sites in Latin America, Vision AI currently supports risk scoring for diabetic retinopathy, glaucoma, age-related macular degeneration, cardiovascular disease, type 2 diabetes, liver fibrosis, and chronic kidney disease. "Another significant advantage will be that our camera will be seamlessly packaged together with our Vision AI platform, allowing us to refer more patients in less time and accurately to medical specialists," added Vargas. "Also, one of our objectives is to integrate other technologies to this preventive screening, expanding the scope from only diabetic patients to patients who have other risk factors and want to prevent other diseases from a more complete approach." The development comes at a critical time for Avant, which is in active talks to acquire Ainnova outright — a move that would consolidate leadership, simplify operations, and unify the companies under one roof ahead of a planned FDA pre-submission meeting scheduled for next month. The two companies already operate jointly through AAC, which holds global licensing rights to Ainnova's technology portfolio and serves as the commercialization engine for Vision AI and all future device deployments. While Vision AI remains compatible with third-party imaging equipment, the decision to design proprietary hardware marks a strategic shift toward product exclusivity — giving Avant greater control over the end-to-end user experience and enhancing its defensibility in a competitive early diagnostics landscape. Also in development are additional platform modules, including a patented dementia detection tool that combines a five-minute blood test with AI-trained algorithms. Although that technology remains in evaluation, the core platform continues to expand its reach and functionality — evolving from a retinal-focused application into a broader engine for predictive healthcare. "Our purpose is to create the future of early disease detection in an accessible way, so that patients can get a preventive check-up anywhere, at a low cost, and easily," said Vargas in a previous statement. "We want to prevent patients with risk factors from developing other diseases that could have been avoided before they became a real problem. To this end, we are seeking to integrate new technologies into our portfolio within a single platform, both through our R&D efforts and through potential exclusive licenses or acquisitions." As the camera prototype nears completion, Avant is positioning itself for broader market entry. While a launch date has yet to be announced, the integrated platform is designed to reduce diagnostic friction, speed up referrals, and expand access to early-stage health insights — especially in geographies where affordability, not innovation, remains the primary barrier to care. With hardware now entering the pipeline, software validated in clinical settings, and corporate consolidation on the table, Avant is no longer just building an AI model — it's building a diagnostic system. Medtronic plc (NYSE: MDT) capped off its fiscal year with strong Q4 results, reporting $8.9 billion in revenue and double-digit earnings growth. "We had a strong close to our fiscal year, and I'm excited to see the progress we are making as our growth drivers continue to build momentum," said Geoff Martha, Chairman and CEO of Medtronic. "The underlying fundamentals of our business are strong, and they are getting stronger." The company highlighted progress across growth franchises, including the launch of BrainSense™ Adaptive Deep Brain Stimulation (aDBS) — its largest-ever commercial rollout of brain-computer interface technology, a milestone in precision neuromodulation. Additionally, Medtronic's AiBLE™ spine surgery ecosystem and connected insulin delivery platforms further signal its growing focus on AI-integrated healthcare solutions. Butterfly Network, Inc. (NYSE: BFLY) kicked off 2025 with strong execution, growing Q1 revenue 20% year-over-year to $21.2 million and narrowing its net loss to $14 million. "2025 is off to a great start. The Butterfly team hit the mark again, delivering right on target with a 20% growth quarter," said Joseph DeVivo, President, CEOah and Chairman of Butterfly Network. "We're very proud of how the Company continues to mature." The company advanced its Butterfly HomeCare pilot program and added two new AI developers to its Butterfly Garden, while existing partner DESKi secured FDA clearance for its AI-driven HeartFocus cardiac app. Its portable iQ3 ultrasound device continued gaining traction, featured on HBO Max's The Pitt and adopted by major U.S. med schools. With a strengthened balance sheet and increasing AI integration, Butterfly reiterated guidance for $96–100 million in 2025 revenue. Oracle Corporation (NYSE: ORCL), through its subsidiary Oracle Health, in partnership with Cleveland Clinic and G42, has announced a strategic collaboration to develop a global AI-powered healthcare delivery platform. The initiative will combine Oracle's cloud and AI infrastructure with Cleveland Clinic's clinical expertise and G42's advanced AI models to deliver scalable, secure, and affordable care. "Aging populations, rising costs, and the complexity of care demand a complete reinvention of how healthcare is provided," said Larry Ellison, Executive Chairman and CTO of Oracle. " Oracle's AI Data Platform and suite of clinical applications can help us understand disease and population health in ways that fuel scientific breakthroughs, reduce the cost of care delivery, and improve patient care. Together with Cleveland Clinic and G42, we will deliver the modern tools providers need to help people live longer, healthier lives." Designed to support precision medicine and real-time clinical intelligence, the platform aims to improve outcomes while reducing costs across the U.S., UAE, and beyond. Recursion Pharmaceuticcals, Inc. (NASDAQ: RXRX) announced early Phase 2 results from its TUPELO trial evaluating REC-4881 in patients with Familial Adenomatous Polyposis (FAP), a rare genetic disorder with no approved therapies. "For patients with FAP, who currently lack FDA-approved treatment options, Recursion's AI-powered Recursion OS platform identified a promising approach through MEK 1/2 inhibition," said Najat Khan, PhD, Chief R&D Officer and Chief Commercial Officer at Recursion. "By analyzing cellular models of APC gene loss, we uncovered a potential first-in-disease treatment and are excited to share our preliminary findings." The AI-discovered MEK1/2 inhibitor reduced polyp burden by a median of 43% in just 13 weeks among evaluable patients, with 83% showing clinical response. The study also reported improvements in upper GI disease severity and a manageable safety profile consistent with known MEK inhibitors. REC-4881 was developed through Recursion's in-house AI platform, Recursion OS, which analyzed APC gene loss models to generate a novel treatment pathway. CONTACT: Equity Insider [email protected] (604) 265-2873 DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. Equity Insider is a wholly-owned subsidiary of Market IQ Media Group, Inc. ("MIQ"). MIQ has been paid a fee for Avant Technologies Inc. advertising and digital media from the company directly. There may be 3rd parties who may have shares Avant Technologies Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Avant Technologies Inc. which were purchased in the open market. MIQ reserves the right to buy and sell, and will buy and sell shares of Avant Technologies Inc. at any time thereafter without any further notice. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material disseminated by MIQ has been approved by the above mentioned company; this is a paid advertisement, and we own shares of the mentioned company that we will sell, and we also reserve the right to buy shares of the company in the open market, or through other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.